CoChat
Sign Up
Cited by 434Cannabis and Cannabinoid ResearchRheumatoid Arthritis Research and TherapiesNatural Compounds in Disease Treatment

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis

Blake, D. R., Robson, P., Ho, M., Jubb, R. W., McCabe, C. S.·2006·Rheumatology
DOI 10.1093/rheumatology/kei183
Open this paper in CoChat — free account

Abstract

OBJECTIVES: To assess the efficacy of a cannabis-based medicine (CBM) in the treatment of pain due to rheumatoid arthritis (RA). METHODS: We compared a CBM (Sativex) with placebo in a randomized, double-blind, parallel group study in 58 patients over 5 weeks of treatment. The CBM was administered by oromucosal spray in the evening and assessments were made the following morning. Efficacy outcomes assessed were pain on movement, pain at rest, morning stiffness and sleep quality measured by a numerical rating scale, the Short-Form McGill Pain Questionnaire (SF-MPQ) and the DAS28 measure of disease activity. RESULTS: Seventy-five patients were screened and 58 met the eligibility criteria. Thirty-one were randomized to the CBM and 27 to placebo. Mean (S.D.) daily dose achieved in the final treatment week was 5.4 (0.84) actuations for the CBM and 5.3 (1.18) for placebo. In comparison with placebo, the CBM produced statistically significant improvements in pain on movement, pain at rest, quality of sleep, DAS28 and the SF-MPQ pain at present component. There was no effect on morning stiffness but baseline scores were low. The large majority of adverse effects were mild or moderate, and there were no adverse effect-related withdrawals or serious adverse effects in the active treatment group. CONCLUSIONS: In the first ever controlled trial of a CBM in RA, a significant analgesic effect was observed and disease activity was significantly suppressed following Sativex treatment. Whilst the differences are small and variable across the population, they represent benefits of clinical relevance and show the need for more detailed investigation in this indication.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/rheumatology/kei183

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

Sorted by citations

Items 401–434 of 434

Related

See all

Metadata

Authors
Blake, D. R., Robson, P., Ho, M., Jubb, R. W., & McCabe, C. S.
Affiliations
  • Royal National Hospital for Rheumatic Diseases (GB)
  • University of Oxford (GB)
  • Northampton General Hospital (GB)
  • Selly Oak Hospital (GB)
Corresponding author
Blake, D. R.
ORCID
McCabe, C. S.
Venue
Rheumatology
Publisher
Oxford University Press (OUP)
Published
2005-11-09
Volume
45
Issue
1
Pages
50-52
ISSN
  • 1462-0324 (ISSN-L)
  • 1462-0332
DOI
10.1093/rheumatology/kei183
OpenAlex
W2155565260
Cited by
433
References
10
Citations by year
2026: 16 · 2025: 24 · 2024: 25 · 2023: 19 · 2022: 45 · 2021: 34 · 2020: 37 · 2019: 35 · 2018: 31 · 2017: 19 · 2016: 22 · 2015: 14 · 2014: 18 · 2013: 11 · 2012: 16
FWCI
6.37
Type
journal article
Language
en
Open access
closed
Locations
  • Lara D. Veeken (publishedVersion)
  • PubMed (publishedVersion)
Funders
GW Pharmaceuticals
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
Keywords
Sativex, cannabis-based medicines, rheumatoid arthritis, pain, oromucosal spray, analgesia, disease activity, sleep quality, morning stiffness, tolerability, adverse effects
MeSH terms
Administration, Oral, Analgesics, Arthritis, Rheumatoid, Cannabidiol, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Pain, Pain Measurement, Plant Extracts, Dronabinol, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review